PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth above 1.5x TRVN's 1.02%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-4.31%
Negative yoy D&A while TRVN is 1.20%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-1173.94%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-7.99%
Both cut yoy SBC, with TRVN at -1.85%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
214.02%
Well above TRVN's 8.38% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Both negative yoy AP, with TRVN at -1687.60%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
259.96%
Growth well above TRVN's 8.60%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
1173.94%
Some yoy increase while TRVN is negative at -52.21%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
18.46%
Some CFO growth while TRVN is negative at -23.12%. John Neff would note a short-term liquidity lead over the competitor.
36.17%
Lower CapEx growth vs. TRVN's 100.00%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
Lower net investing outflow yoy vs. TRVN's 100.00%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Both yoy lines negative, with TRVN at -84.49%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.